Wish Lists

Cart

For suppliers Contact us

Homepage > Company > Media > Pharma News > 2017 > Teva loses $235m patent trial to GSK

Teva loses $235m patent trial to GSK

A US court dismissed Teva's claim that GlaxoSmithKline's patent for the Coreg drug was invalid.

A US court yesterday ordered Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) to pay $235 million compensation to GlaxoSmithKline for violation of the latter's patent for its Coreg drug, used to treat chronic heart failure.

The prevalent practice in the generic drug industry is for generic companies to attack a patent with a claim that it has expired, while launching a generic version of it. The innovative drug companies characteristically claim that the patent is still valid, thereby gaining more time to enjoy exclusivity for the original drug.

A generic drug company launching the first generic version of an innovative drug receives a certain period of exclusivity for its generic version, but runs the risk that a court will rule that the original patent did not expire, in which case the generic company has to pay damages to the ethical drug company.

Published by Globes [online], Israel Business News - www.globes-online.com - on June 22, 2017

http://www.globes.co.il/

Read also

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...

0 items in Cart

Cart Subtotal:

Go to cart

You will be able to Pay Online or Request a Quote

We use "cookies* to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies